Today: The Retrophin Inc. (RTRX) CEO Sold $173,184.00 in Stock

The Retrophin Inc. (RTRX) CEO Sold $173,184.00 in Stock

Retrophin Inc. (NASDAQ:RTRX) CEO Steve Aselage sold 8,200 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $21.12, for a total value of $173,184.00. Following the sale, the chief executive officer now owns 248,756 shares in the company, valued at approximately $5,253,726.72. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Retrophin Inc. (NASDAQ:RTRX) opened at 21.64 on Monday. The company has a 50 day moving average price of $20.48 and a 200-day moving average price of $19.02. The firm’s market capitalization is $816.52 million. Retrophin Inc. has a 12 month low of $11.60 and a 12 month high of $24.57.

Retrophin (NASDAQ:RTRX) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.38 by $0.47. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The firm earned $33.95 million during the quarter, compared to analyst estimates of $34.84 million. During the same quarter in the previous year, the business posted ($0.05) EPS. Retrophin’s revenue was up 21.2% compared to the same quarter last year. Equities research analysts expect that Retrophin Inc. will post ($1.32) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. American International Group Inc. boosted its position in shares of Retrophin by 1.7% in the second quarter. American International Group Inc. now owns 20,847 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 351 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Retrophin by 1.4% in the second quarter. ProShare Advisors LLC now owns 31,730 shares of the biopharmaceutical company’s stock worth $565,000 after buying an additional 425 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Retrophin by 1.1% in the third quarter. California State Teachers Retirement System now owns 76,738 shares of the biopharmaceutical company’s stock worth $1,717,000 after buying an additional 800 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Retrophin by 3.8% in the second quarter. Nationwide Fund Advisors now owns 23,344 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 862 shares during the last quarter. Finally, BlackRock Group LTD boosted its position in shares of Retrophin by 8.6% in the third quarter. BlackRock Group LTD now owns 15,448 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 1,219 shares during the last quarter.

Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Retrophin from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Leerink Swann upped their price target on Retrophin from $27.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, September 7th. JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research report on Friday, November 4th. BMO Capital Markets reaffirmed an “outperform” rating and set a $28.00 price objective (up from $25.00) on shares of Retrophin in a research report on Monday, August 8th. Finally, TheStreet cut Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, November 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $29.60.

Retrophin Company Profile

Related posts

Leave a Comment